Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) Latest Company News

Oct 23, 2026, 10:35 UTC
Anke Bio reported revenue of 1.652 billion yuan and attributable net profit of 468 million yuan for the first three quarters of 2026, down 15.81% and 15.15% year over year, respectively.
Source:
- finance.sina.cn
Oct 23, 2026, 10:35 UTC
Anke Bio reported third-quarter 2026 revenue of 554 million yuan, down 17.31% year over year, and attributable net profit of 136 million yuan, down 26.68%.
Source:
- finance.sina.cn
Oct 20, 2026, 10:13 UTC
China's National Medical Products Administration approved Anke Bio's AK2401 injection, a pembrolizumab biosimilar, for clinical trials in solid tumors.
Source:
- finance.sina.cn
Sep 21, 2026, 07:57 UTC
Anke Bio's clinical trial application for its self-developed innovative drug AK2405 for injection, a HER2-targeting antibody-drug conjugate, was accepted by the National Medical Products Administration.
Source:
- finance.sina.cn
Sep 17, 2026, 17:33 UTC
Anke Bio and Shenshi Technology signed a strategic cooperation agreement to collaborate on AI4S-enabled design and optimization of ADC payload molecules for innovative drug development.
Source:
- money.udn.com
Sep 16, 2026, 10:54 UTC
Anke Bio and DP Technology signed a strategic cooperation agreement to collaborate on AI-driven molecular design and optimization of antibody-drug conjugate payloads.
Source:
- finance.sina.cn
Sep 15, 2026, 19:53 UTC
Anke Bio's PA3-17, the world's first autologous CD7-CAR-T cell therapy, entered China's breakthrough therapy designation and is expected to complete pivotal Phase II trials in September and industrialize globally by end-2027.
Source:
- wap.eastmoney.com
Aug 28, 2026, 10:27 UTC
Anke Bio announced it will acquire the remaining 27.4647% equity in Anke Yuliangqing from several shareholders for 54.3238 million yuan, making it a wholly-owned subsidiary.
Source:
- finance.sina.cn
Aug 25, 2026, 11:17 UTC
Anke Bio announced its first-half 2026 results: revenue of 1.098 billion yuan, down 15.04% year-on-year; net profit attributable to shareholders of 332 million yuan, down 9.33% year-on-year; and no dividend or share transfer plan.
Source:
- finance.sina.cn
Aug 17, 2026, 11:15 UTC
Anke Bio's marketing authorization application for Cetrorelix Acetate for Injection was accepted by China's National Medical Products Administration.
Source:
- finance.sina.cn
Jul 10, 2026, 12:04 UTC
Anke Biological and its subsidiaries had 20 products included in the National Essential Drug List (2026 edition), with 3 new additions: trastuzumab injection, tenofovir alafenamide fumarate tablets, and Qingre Jiedu oral liquid.
Source:
- finance.sina.cn

300009.SZ

Anke Bio reported revenue of 1.652 billion yuan and attributable net profit of 468 million yuan for the first three quarters of 2026, down 15.81% and 15.15% year over year, respectively.

Anke Bio reported third-quarter 2026 revenue of 554 million yuan, down 17.31% year over year, and attributable net profit of 136 million yuan, down 26.68%.

China's National Medical Products Administration approved Anke Bio's AK2401 injection, a pembrolizumab biosimilar, for clinical trials in solid tumors.

Anke Bio's clinical trial application for its self-developed innovative drug AK2405 for injection, a HER2-targeting antibody-drug conjugate, was accepted by the National Medical Products Administration.

Anke Bio and Shenshi Technology signed a strategic cooperation agreement to collaborate on AI4S-enabled design and optimization of ADC payload molecules for innovative drug development.

Anke Bio and DP Technology signed a strategic cooperation agreement to collaborate on AI-driven molecular design and optimization of antibody-drug conjugate payloads.

Anke Bio's PA3-17, the world's first autologous CD7-CAR-T cell therapy, entered China's breakthrough therapy designation and is expected to complete pivotal Phase II trials in September and industrialize globally by end-2027.

Anke Bio announced it will acquire the remaining 27.4647% equity in Anke Yuliangqing from several shareholders for 54.3238 million yuan, making it a wholly-owned subsidiary.

Anke Bio announced its first-half 2026 results: revenue of 1.098 billion yuan, down 15.04% year-on-year; net profit attributable to shareholders of 332 million yuan, down 9.33% year-on-year; and no dividend or share transfer plan.

Anke Bio's marketing authorization application for Cetrorelix Acetate for Injection was accepted by China's National Medical Products Administration.

Anke Biological and its subsidiaries had 20 products included in the National Essential Drug List (2026 edition), with 3 new additions: trastuzumab injection, tenofovir alafenamide fumarate tablets, and Qingre Jiedu oral liquid.